A clinical trial showed that taking ubrogepant during the prodromal phase of a migraine, prior to headache onset, can reduce symptoms such as sensitivity to light, fatigue, neck pain, and trouble concentrating. The study included 477 participants and found that ubrogepant consistently outperformed placebo in relieving symptoms as early as 1 hour post-dose.

Source: Nature Medicine